01 / THE ARGUMENT
A richer benefit still needs an operating model
The 2026 defined standard Part D benefit has a $615 deductible and a $2,100 annual out-of-pocket threshold for covered Part D drugs. CMS's final instructions, issued April 7, 2025, describe the 2026 redesign and changes in sponsor, manufacturer and federal liability. The threshold caps a beneficiary’s covered Part D out-of-pocket liability; it should not be described as a cap on every healthcare bill or every medicine a person might purchase.[1]
For an executive, the decision is where to connect this financing change to the actual medication journey. A prescription can be clinically appropriate yet remain unfilled because the person misunderstands the benefit, the pharmacy has an unresolved claim, the prescriber lacks a required response, or delivery is impractical. My proposed unit of management is one medication episode from the treatment decision through receipt, continued access and the clinician's reassessment. A benefit parameter becomes useful when the next operational step is clear.
02 / THE ARGUMENT
Separate affordability from liquidity
The Medicare Prescription Payment Plan is voluntary and lets participants spread covered out-of-pocket prescription costs across the calendar year through plan billing. Medicare explicitly states that it does not lower drug costs. Annual exposure and monthly payment timing are different problems, and neither should be sold as the other.[2]
That distinction belongs in the service design. The first conversation should establish the person's coverage, current medication-access barrier, expected timing and preference. A cash-flow problem may call for an explanation of the payment option and referral to the plan. A total-cost problem may call for review of available assistance or benefit alternatives. A coverage problem requires the applicable plan and prescribing workflow. Education should leave the person able to make an informed choice, rather than maximizing opt-ins to a single program.
03 / THE ARGUMENT
The clinical evidence informs the question, not the answer
A USC-led scoping review examined 32 US studies concerning insurance design and care for people with multiple sclerosis. Greater out-of-pocket spending was associated with lower disease-modifying-therapy adherence and more discontinuation, while specialty-pharmacy access was associated with better adherence. This is disease-specific evidence assembled from studies available through February 2022; it is not a causal evaluation of the new Medicare benefit.[3]
I would use that evidence to justify measuring medication continuity, then require local evidence to establish effect. Distinguish a refill becoming financially possible from a refill being obtained, and distinguish possession from safe, appropriate use. Clinical teams retain the authority to initiate, change or stop treatment. A program that increases fills despite an appropriate discontinuation would perform well on a simplistic adherence dashboard while failing its clinical purpose. Record intentional discontinuation and plan changes separately from access-related interruption.
04 / THE ARGUMENT
Create a shared access ledger with bounded responsibilities
My recommended payer-provider-pharmacy arrangement uses a medication-access ledger containing the current plan, coverage response, responsible prescriber, dispensing site, documented barrier, next action and agreed communication channel. The ledger should support the work already assigned to each institution. It should not create a new parallel inbox whose apparent completeness depends on manual reconciliation nobody has funded.
Begin with a defined population and an access-intensive therapy class. The plan owns benefit and payment-option questions; the pharmacy confirms dispensing and supply constraints; the prescriber addresses clinical decisions and necessary documentation; an accountable coordinator follows unresolved handoffs. Service-level terms should specify response deadlines, urgent escalation and patient communication. Contractual scope should include data quality, changes in coverage and staff effort after an exception, because those costs determine whether a promising process survives routine operations.
05 / THE ARGUMENT
Finance the whole episode and test value honestly
A provider, a pharmacy and a Part D sponsor may experience different financial consequences from the same resolved access problem. My recommendation is to map those consequences before selecting a payment model. Count the incremental labor and integration cost, the dispensing or service margin where applicable, and any separately established change in medical utilization. Avoid adding each party's gross revenue to produce a fictional system-wide return. Transfers between parties and net new value are different economic quantities.
The evaluation should follow initial access, interruptions, patient burden and clinically appropriate continuation. Compare a defined service cohort with a credible alternative and explain selection differences. Keep improvements in payment timing distinct from reductions in cost, and reported satisfaction distinct from clinical outcomes. The stop rule is straightforward: reconsider the service if access remains unresolved, workload merely shifts to clinicians or pharmacies, or improved fill rates depend on increased patient burden. Scale a workflow that improves the episode at a sustainable marginal cost, rather than a dashboard that celebrates benefit education alone.
FROM EVIDENCE TO ALLOCATION
The operating and investment case
Proposed design by Azis R. Dabas. These decisions and evaluation criteria are not outcomes established by the cited studies.
- Decision
- Commission a payer-provider-pharmacy continuity service for one defined Medicare population and an access-intensive therapy class before wider expansion.
- Accountable owner
- Part D benefit operations and a provider pharmacy or population-health leader, with dispensing partners, clinical oversight and finance validation.
The delivery sequence
- Confirm the current benefit and medication-access barrier.
- Separate annual cost exposure, monthly payment timing, coverage restrictions and delivery constraints.
- Offer accurate benefit education and route payment-plan choices to the plan.
- Assign unresolved clinical, coverage and dispensing tasks to the responsible institution.
- Confirm receipt and the clinician's plan for appropriate continuation or discontinuation.
- Reconcile episode costs and patient outcomes across partners.
The economics
Evaluate net incremental service value after staffing, integration, pharmacy and provider workload, and patient burden. Count financial transfers once. Do not assume the payment plan reduces drug prices or that higher fills generate medical savings.
The measures that govern expansion
- Time to first appropriate dispense
- Access-related therapy interruptions
- Resolution time by barrier type
- Patient understanding and financial burden
- Clinically appropriate continuation and documented discontinuation
- Provider and pharmacy exception-work minutes
- Net episode cost and separately validated downstream outcomes
Stop or redesign when
Pause expansion if payment timing is represented as a discount, clinical authority is obscured, unresolved work is displaced to partners, or continuity improves only by increasing patient burden.
THE EVIDENCE LEDGER
What supports the argument
Study findings, policy requirements and market signals support different claims. Their boundaries remain visible.
[1] policy · April 7, 2025
Final CY 2026 Part D Redesign Program Instructions
- Design or status
- Official final program instructions summary
- Verified finding
- The 2026 defined standard benefit has a $615 deductible and $2,100 annual covered-Part-D out-of-pocket threshold, with revised liability among sponsors, manufacturers and CMS.
- Boundary
- Defined-standard-benefit parameters and CY 2026 policies; not a guarantee that every medicine or healthcare expense is covered.
[2] policy · Undated live guidance; verified 2026-10-07
What's the Medicare Prescription Payment Plan?
- Design or status
- Official beneficiary guidance
- Verified finding
- The voluntary option spreads covered prescription out-of-pocket costs through plan billing across the calendar year; it does not lower drug costs.
- Boundary
- General explanation, not an individualized assessment of whether participation will help a particular beneficiary.
[3] peer-reviewed · September 12, 2023
The impact of medical insurance on health care access and quality for people with multiple sclerosis in the United States: A scoping review
- Design or status
- PRISMA-ScR scoping review of 32 US studies; literature through February 2022
- Verified finding
- Higher out-of-pocket spending was associated with worse disease-modifying-therapy adherence and greater discontinuation; specialty-pharmacy access was associated with better adherence.
- Boundary
- Disease-specific heterogeneous evidence predating the 2026 benefit; association does not establish the new redesign's effect.
FOLLOW THE SOURCE
Sources and editorial method
Selected evidence was reviewed through October 7, 2026. Numbered references connect claims to their underlying records. Economic mechanisms and business cases are the author’s analysis unless a source is cited. The review is selective; publication dates retain the precision available in the source.
Final CY 2026 Part D Redesign Program Instructions
Centers for Medicare & Medicaid Services. CMS Fact Sheet. . policy.
What's the Medicare Prescription Payment Plan?
Centers for Medicare & Medicaid Services. Medicare.gov. Undated live guidance; verified 2026-10-07. policy.
The impact of medical insurance on health care access and quality for people with multiple sclerosis in the United States: A scoping review
Nuriel Moghavem, Gloria Del Rosario Castañeda, Amy J Chatfield, Lilyana Amezcua. Multiple Sclerosis Journal; issue March 2024. . peer-reviewed.
DOI: 10.1177/13524585231197275 · Primary verification record · Consensus paper record
Study authors retain credit for their work. Researcher affiliations and publisher names do not imply affiliation with or endorsement of this analysis.